Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonapanitase after angioplasty in PAD
NCT02956993Phase 1Completed
- Sponsor
- Proteon Therapeutics
- Start
- Nov 2016
- Primary completion
- Apr 2019
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in peripheral artery disease (PAD) comparing Vonapanitase with Placebo (2 arms). Primary endpoints: Incidence of adverse events at 6 months and Technical success of perivascular injection. Started Nov 2016; status: completed.
02
Drugs
vonapanitase
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT02956993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956993.